Articles from AL-S Pharma AG

AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced new analyses from its global Phase 2 clinical trial (AP101-02) evaluating the company's Phase 3-ready lead program, AP-101, in patients with sporadic ALS and superoxide dismutase 1 (SOD1)-ALS. The new findings demonstrate greater preservation of body weight in patients treated with AP-101 compared with placebo. Weight loss has been associated with shorter survival, while longitudinal changes in weight may reflect several aspects of disease progression, including nutritional status, metabolic changes, and muscle loss.

AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the appointment of Harry Welten as chief executive officer (CEO). Mr. Welten succeeds Michael Salzmann, Ph.D. The Company recently reported positive topline results from a Phase 2 study of its lead program AP-101, a human monoclonal antibody targeting misfolded superoxide dismutase 1 (SOD1). AL-S Pharma is currently advancing AP-101 toward a confirmatory Phase 3 clinical trial in ALS which it aims to initiate in 2027.

AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the presentation of clinical data from the global Phase 2 clinical trial (AP-101-02) evaluating the company’s Phase 3-ready lead program, AP-101, in patients with ALS. The AP-101-02 clinical trial results were featured today in a poster presentation at the European Network to Cure ALS (ENCALS) 2026 Congress.

AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the presentation of new clinical data from the global Phase 2 clinical trial (AP-101-02) evaluating the company’s lead program, AP-101, in patients with ALS. AP-101 is an investigational human-derived antibody directed against misfolded superoxide dismutase 1 (SOD1). AP-101 is designed to inhibit the spread of SOD1 pathology in the central nervous system of people living with ALS, helping the body’s immune system clear these harmful proteins.1